Miturox (Mitomycin)

Mitomycin, the active ingredient in Miturox, is an antineoplastic antibiotic presented as an intravesical solution for intravesical use. It is employed in the treatment of non‑muscle invasive bladder cancer, targeting malignant cells within the bladder lining of adult patients who have undergone transurethral resection.

GNH USA supplies Miturox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, ensuring consistent quality and regulatory compliance across markets.

Miturox (mitomycin) is used as intravesical chemotherapy for bladder cancer.

- Non‑muscle invasive bladder cancer: reduces tumor recurrence and progression after transurethral resection. - Carcinoma in situ of the bladder: helps eradicate residual malignant cells.

Common Side Effects: - Bladder irritation: burning or discomfort during urination. - Dysuria: painful urination. - Urinary frequency: increased urge to void. - Hematuria: presence of blood in urine. - Mild pelvic pain. - Local infection risk.

Serious or Rare Side Effects: - Systemic bone marrow suppression leading to anemia or neutropenia. - Renal toxicity with impaired kidney function. - Severe allergic reactions such as anaphylaxis. - Pulmonary fibrosis or interstitial lung disease. - Secondary malignancies due to DNA damage. - Life‑threatening hemorrhage.

Miturox should be used only under specialist supervision with careful patient assessment.

- Patient selection: indicated for adults with non‑muscle invasive bladder cancer after complete transurethral resection. - Renal function: evaluate creatinine clearance before each administration. - Bladder integrity: avoid if active infection, perforation, or severe inflammation is present. - Systemic exposure: monitor complete blood counts for signs of marrow suppression. - Pregnancy and lactation: contraindicated; avoid use in pregnant or nursing women. - Store at room temperature: keep in original container, protect from light and moisture.

Miturox may interact with other agents that affect bladder toxicity or systemic bone‑marrow function.

Major Interactions (Avoid): - Concurrent alkylating agents: additive cytotoxicity increases risk of severe marrow suppression. - Pelvic radiation therapy: heightened bladder irritation and ulceration. - Strong CYP450 inducers (if applicable to metabolism): may reduce mitomycin exposure.

Moderate Interactions (Monitor Closely): - Nephrotoxic antibiotics (e.g., aminoglycosides): monitor renal function. - NSAIDs: potential for increased renal impairment. - Antifungal agents (e.g., azoles): may augment bone‑marrow toxicity.